Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456261 · ClinicalTrials.gov registry record · Phase 2
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00456261 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 110 participants.
The verdict
NCT00456261, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small cell lung cancer. The primary objective in this study is to see how well this combination of drugs keeps the cancer from getting worse in this elderly population of non-small cell lung cancer patients.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456261
The ClinicalTrials.gov registry entry for NCT00456261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00456261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00456261 about?
NCT00456261 is a clinical study titled "First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC". This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small c...
What is the current status of trial NCT00456261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2007-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00456261?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00456261?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.